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Background: Microglia are resident mononuclear phagocytes of the brain that become activated in response to
insults including neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and prion disease. In the
central nervous system the chemokine Cx3cl1 (Fractalkine) is expressed by neurons and its exclusive receptor Cx3cr1 is
expressed solely on microglia. Cx3cl1/Cx3cr1 signalling is thought to maintain microglia in their resting state and
disrupting this equilibrium may allow microglia to become activated. In prion disease, microglial proliferation has been
suggested to contribute to overall disease progression, however, in different mouse models of neurodegeneration, loss
of Cx3cr1 has been shown to either worsen or improve the phenotype depending on the paradigm.
Results: To investigate the role of Cx3cl1/Cx3cr1 signalling in prion disease we infected Cx3cr1 null mice with three
different strains of prions. Following challenge with Chandler/RML, ME7 and MRC2 prion strains, Cx3cr1 knockout mice
showed highly significant reductions in incubation time. No differences were seen in the pattern and localisation of
activated microglia in the brain or in the mRNA expression levels of chemokines/cytokines (Cxcl10, Il-12b, Il-1b, Arg-1
and Cxc3l1).
Conclusion: Our data suggest a protective role for Cx3cl1/Cx3cr1 cross-talk in prion disease.
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Neuroinflammation within the brain is a common fea-
ture of neurodegeneration and one of the hallmarks of
these changes is the activation of microglia. Microglia
are CNS (central nervous system) mononuclear phago-
cytes that under normal conditions are surveillant but
are activated in response to various brain insults [1,2].
Activation can result in phagocytosis and the release of
substances such as neurotrophic factors and cytokines/
chemokines [3]. While some of these functions are likely
to be beneficial, it has been proposed that an excess of
particularly proinflammatory cytokines may be damaging
and that this immune response may contribute to dis-
ease pathogenesis.
Neurons express the chemokine Cx3cl1 (fractalkine) in
a membrane bound or soluble form. Its receptor within
the CNS, Cx3cr1, is expressed solely on microglia [4-6].* Correspondence: s.lloyd@prion.ucl.ac.uk
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article, unless otherwise stated.Cx3cl1 is thought to act as a chemoattractant recruiting
microglia to sites of injury and the normal signalling be-
tween Cx3cl1 and Cx3cr1 is thought to provide part of
the neuronal-microglial cross talk that maintain micro-
glia in their resting state [2].
The role of Cx3cr1 has been extensively studied in many
models of neurodegeneration and brain injury through the
use of Cx3cr1 knockout mice, although often with con-
flicting results. In a triple transgenic (3xTg: PS1M146V
knock-in, transgenic APPSwe and tauP301L) model of Alz-
heimer’s disease (AD) it was shown that loss of Cx3cr1 re-
sulted in the increase of microglial migration and
prevented neuronal loss while levels of Aβ deposition
remained unaltered [7]. The effect of Cx3cl1/Cx3cr1 sig-
nalling seen in the 3xTg model contrasts with the findings
reported for both the APPPS1 and R1.40 models of AD
where loss of Cx3cr1 altered microglial activation and
reduced Aβ deposition [8]. Knockout of Cx3cr1 in a
toxin-induced model of Parkinson’s disease (PD) and a
genetic model of Amyotrophic Lateral Sclerosis (ALS) (Tg
SOD1G93A) worsened the phenotype, in both cases produ-
cing more neuronal loss and, for the ALS model,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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reduced survival were also seen [9]. In related experiments
with a toxin-induced model of PD in rats, treatment with
the ligand Cx3cl1 was neuroprotective with reduced
microglial activation [10]. In addition, in a model of tauo-
pathy, a humanised MAPT transgenic mouse also lacking
Cx3cr1 showed altered microglial activation, enhanced tau
phosphorylation and aggregation as well as poorer spatial
working memory [11]. In contrast, smaller infarcts and
better functional recovery was seen in the absence of
Cx3cr1 in a model of ischaemia [12].
Prion diseases or transmissible spongiform encephal-
opathies (TSEs) are progressive neurodegenerative dis-
eases that include Creuzfeldt-Jakob disease (CJD) in
humans, bovine spongiform encephalopathy (BSE) in
cattle and scrapie in sheep [13]. In common with many
other neurodegenerative diseases, a key feature of prion
diseases is the accumulation of aggregates of an abnor-
mally folded protein. In prion diseases these misfolded
protein aggregates propagate by the conversion of nor-
mal cellular prion protein (PrPC) to abnormal isoforms,
designated PrPSc and constitute lethal infectious agents.
Prion infection is accompanied by spongiform change
and neuronal loss in the brain. In contrast to other in-
fectious diseases little if any evidence of inflammation is
seen in the periphery. However, even before significant
neuronal loss occurs, there is widespread activation of
microglia, glia and astrocytes in the brain [14-16]. Proin-
flammatory cytokines increase during disease progres-
sion, however, this is greatly reduced relative to that
seen during bacterial or viral infections [15,17].
In wild type mice infected with a mouse-adapted scra-
pie prion strain (ME7) Cx3cl1 is reported to be upregu-
lated in astrocytes but there is no change in surviving
neurons and Cx3cr1 expression is also upregulated on
microglia [4]. Analysis of hamster brains infected with
the prion strain 263K showed that Cx3cl1 is downregu-
lated during disease progression [18]. These data, to-
gether with the prominence of activated microglia early
in prion disease and the parallels with other neurode-
generative disorders, suggest that Cx3cl1/Cx3cr1 signal-
ling may play an important role in prion disease
pathogenesis. To evaluate this hypothesis we challenged
Cx3cr1 knockout mice with three different prion strains
[5]. Our results show that for two mouse-adapted scra-
pie strains (Chandler/RML and ME7) and a mouse-
passaged BSE strain (MRC2), Cx3cr1 deficiency shortens
the incubation time thereby suggesting that Cx3cl1/
Cx3cr1 signalling is partially protective in prion disease.
Methods
Animals
Cx3cr1+/- mice (Cx3cr1/GFP, C.129P2-Cx3cr1tm1Litt/leg)
on a Balb/c background were obtained as embryos fromthe European Mouse Mutant Archive, resurrected and
bred to homozygosity [5]. Wild type Balb/cOlaHsd mice
were purchased from Harlan, UK Ltd (Bicester, UK).
Prion transmission
Inocula for three different prion strains were made from
the brains of terminally sick mice as 1% (weight/volume)
homogenates in sterile D-PBS. Chandler/RML (I9900)
and ME7 (I9459) are two different mouse-adapted
strains of scrapie and MRC2 (I9468) is a mouse-
passaged strain of BSE [19,20]. Following anaesthesia
with isofluorane/O2, female mice were inoculated intra-
cerebrally with 30 μl of inocula into the right parietal
lobe as previously described [21]. Mice were examined
daily for clinical signs of prion disease and were culled
once a definitive diagnosis had been made or earlier if
showing any signs of distress or excessive weight loss.
Diagnostic signs of clinical prion disease include ataxia,
impaired righting reflex and a sustained hunched pos-
ture [22]. Incubation time was defined as the number of
days from inoculation to confirmed diagnosis. The
Kaplan-Meier log-rank test was used to analyse survival
data using the statistical package SPSS (IBM). Animals
were housed, maintained and cared for in accordance
with institutional, UK and international regulations and
standards on animal welfare and conform to ARRIVE
guidelines [23]. Ethical approval was granted by the
Medical Research Council Prion Unit animal research
ethics committee and carried out under UK Home Of-
fice licence PPL70/7274.
Neuropathology and immunohistochemistry
Mouse brains were fixed in 10% buffered formal saline
(BFS) and prion-infected tissue was treated in 98% for-
mic acid for one hour to remove infectivity. Tissues were
paraffin wax embedded, sagitally sectioned and stained
as previously described [22]. Haematoxylin and eosin
(H&E) stained sections were assessed to determine the
relative levels and distribution of spongiosis and neur-
onal loss. Prion deposition was evaluated with the anti-
PrP monoclonal antibody ICSM35 (D-Gen Ltd, UK) and
gliosis was determined with an anti-glial fibrillary acid
protein (GFAP) antibody (Dako Ltd, UK). Microglia were
visualised by staining with an anti-Iba1 polyclonal anti-
body (Wako).
Real-time RT-PCR
RNA was extracted using a TRIzol Plus RNA Purifica-
tion kit (Life Technologies) from half brains taken from
terminally sick prion infected mice and uninfected con-
trols (n = 4 or 5 per group). cDNA was generated using
a QuantiTect Reverse Transcription Kit (Qiagen). Con-
taminating genomic DNA was removed during the extrac-
tion with a DNase I digestion and this was confirmed by
Figure 1 Kaplan-Meier survival curves. Data are shown as % of
surviving animals (y-axis) plotted against the number of days post-
inoculation (x-axis). (A) Transmission of Chandler/RML prion strain to
Cx3cr1-/- (n = 25) and Cx3cr1+/+ (WT, n = 24) controls (B) Transmission
of ME7 prion strain to Cx3cr1-/- (n = 22) and Cx3cr1+/+ (WT, n = 24).
(C) Transmission of MRC2 mouse adapted BSE prion strain to Cx3cr1-/-
(n = 23) and Cx3cr1+/+ (WT, n = 21). A reduction in mean incubation
time of 4%, 7%, and 7% was seen in A-C respectively. This reduction in
survival was statistically significant for each transmission P = 0.004
(A) and P < 0.0001 (B and C), Kaplan-Meier log-rank survival test.
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ple. Real-time RT-PCR reactions were carried out using
Taqman Gene Expression Master Mix enzyme (Life Tech-
nologies) on a 7500 Fast Real-time PCR System (Life
Technologies). Gene specific Taqman Gene Expression
assays (Life Technologies) were used for Cxcl10, Il-12b, Il-
1b, Arg-1 and Cx3cl1. Each reaction was duplexed inde-
pendently with two endogenous controls (rodent GAPDH
and mouse β-actin, Life Technologies). All reactions were
carried out in triplicate. Statistical tests were carried out
using GraphPad InStat (GraphPad Software, Inc, Califor-
nia, USA).
Results
Transmission of prions to Cx3cr1-/- mice
Cx3cr1 knockout mice were generated by replacing the
Cx3cr1 gene with the green fluorescent protein (GFP)
reporter gene [5]. The gene targeting results in the loss
of the wild type Cx3cr1 mRNA transcript and the gener-
ation of a chimeric transcript of an untranslated Cx3cr1
exon spliced to the GFP exon. The mice have a normal
lifespan with no visible abnormal phenotype. The pres-
ence of GFP has not been reported to interfere with
microglial function and microglia are still able to be-
come activated in the absence of Cx3cr1 [5]. To investi-
gate the role of Cx3cl1/Cx3cr1 neuronal-glial cross talk
in prion disease we inoculated female Cx3cr1-/- mice
and Balb/c wild type controls intracerebrally with three
different mouse-adapted prion strains. Chandler/RML
and ME7 are two distinct scrapie-derived prion strains
and MRC2 was generated from the passage of cattle BSE
in mice [19,20]. Each of these prion strains transmits
readily to wild type mice and produce a distinctive incu-
bation time and patterns of PrPSc distribution, gliosis
and spongiosis [19]. Onset of diagnostic signs of prion
disease was significantly earlier in Cx3cr1-/- mice relative
to controls for all three prion strains (Figure 1). For
Chandler/RML prions the mean incubation time (days ±
sem) was reduced by 4% from 150 ± 2 in Cx3cr1+/+ to
144 ± 1 in Cx3cr1-/- mice (P = 0.004, Kaplan-Meier log
rank survival) and for ME7 the mean incubation time
was reduced by 7% from 178 ± 1 in Cx3cr1+/+ to 168 ± 1
in Cx3cr1-/- mice (P < 0.0001, Kaplan-Meier log rank sur-
vival). For MRC2 the mean incubation time was reduced
by 7% from 206 ± 2 in Cx3cr1+/+ to 200 ± 1 in Cx3cr1-/-
mice (P < 0.0001, Kaplan-Meier log rank survival).
Neuropathology
Brain sections from terminally sick mice from each
group were evaluated for evidence of neuropathological
changes. Overall, for Chandler/RML inoculated mice,
the patterns of spongiosis, gliosis and PrP distribution
were the same for both wild type and Cx3cr1-/- groups.
Even in the absence of Cx3cl1/Cx3cr1 signalling,microglia show extensive proliferation and based on
morphology appear to be activated and similarly distrib-
uted to that seen in the controls (Figure 2). Similarly, for
ME7 and MRC2 inoculated animals, no differences were
seen in the patterns of spongiosis, gliosis, PrP and
microglia distribution between Cx3cr1-/- and Cx3cr1+/+
groups (Figures 3 and 4). Neuropathological differences
are seen between the three prion strains, however, these
are characteristic of the strains and do not appear to
have been influenced by loss of Cx3cr1.
Prion strains
Prion strains in mice are characterised by their incuba-
tion time, neuropathology and the biochemical proper-
ties of PrPSc [13]. To evaluate the effect of Cx3cr1
Figure 2 Chandler/RML neuropathology. Histological features of Chandler/RML prion transmission to Cx3cr1-/- (A-E) and wild type control (F-J)
mice. Panels A and F show the global distribution of disease-associated PrP using anti-PrP monoclonal antibody ICSM35. Panels B, C, G and H
show staining of microglia with Iba-1 in the hippocampus (B, G) and the thalamus (C, H). Panels D, E, I and J are stained with haematoxylin and
eosin (H&E) to visualise spongiosis and neuronal loss in the hippocampus. Boxes show where the higher power images have been taken and
arrows highlight apoptotic cells. Overall, no differences are seen between Cx3cr1-/- and wild type mice. Scale bar corresponds to 2 mm (A, F), 400 μm
(B, C, D, G, H, I) or 100 μm (E, J).
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teristics we examined the brains of infected animals by
western blotting using the anti-PrP antibody ICSM35.
No differences were seen in PrPSc type between
Cx3cr1-/- and Cx3cr1+/+ animals (Additional file 1 and
Additional file 2: Figure S1).
Cytokine mRNA expression
Based on immunohistochemical staining with Iba1, we
saw no differences in microglial proliferation and distri-
bution between Cx3cr1 knockout and wild type mice.
The activation status of microglia may be inferred by the
relative abundance of various cytokines and chemokines
in the brain. In other models of neurodegeneration in
the absence of Cx3cr1, alterations in the cytokine/che-
mokine environment has been observed [8,11]. We
therefore measured the mRNA levels, by real time RT-
PCR, of various cytokines/chemokines in the brains of
terminally sick mice for each of our three prion strains
and in uninfected controls for both wild type and Cx3cr1
knockout mice. Firstly, we looked at levels of cytokines/
chemokines known to be induced in prion disease
(Cxcl10, Il-12b and Il-1b) [17]. Cxcl10 expression was
significantly increased in all three prion strains relative
to uninfected controls with 5-fold increases for Chandler/RML and ME7 and a 15-fold increase for MRC2 (P < 0.01
for all prion strains,T-test). No significant differences were
seen between knockout and wild type groups (Figure 5A).
Il-12b expression was also significantly increased in all
prion-infected groups (P < 0.05 for all prion strains). How-
ever, a 2-fold increase was seen in Cx3cr1-/- relative to
Cx3cr1+/+ mice (P = 0.01) but only with the ME7 prion
strain (Figure 5B). Il-1b expression was significantly in-
creased in all prion-infected groups (P < 0.01 for all
strains, T-test), however, no significant differences were
seen between Cx3cr1-/- and wild type controls (Figure 5C).
Microglia may be activated through either a classical (M1)
or alternative (M2) pathway [24]. Cxcl10 is a marker of
the M1 pathway and Arg-1 is a marker of the M2 path-
way. As described, Cxcl10 mRNA expression is induced
equally in both Cx3cr1 knockout and wild type mice with
all prion strains, however, no differences were observed
for Arg-1 mRNA expression by mouse genotype or prion
infection (Figure 5D). This suggests that the M1 microglia
activation pathway is triggered by prion infection and this
is not altered by loss of Cx3cr1. We also looked at Cx3cl1
(fractalkine) mRNA expression and saw no significant dif-
ferences between Cx3cr1 knockout and wild type mice or
between infected and uninfected groups (Additional file 1
and Additional file 3: Figure S2).
Figure 3 ME7 neuropathology. Histological features of ME7 prion transmission to Cx3cr1-/- (A-E) and wild type control (F-J) mice. Panels A and
F show the global distribution of disease-associated PrP using anti-PrP monoclonal antibody ICSM35. Panels B, C, G and H show staining of
microglia with Iba-1 in the hippocampus (B, G) and the thalamus (C, H). Panels D, E, I and J are stained with haematoxylin and eosin (H&E) to
visualise spongiosis and neuronal loss in the hippocampus. Boxes show where the higher power images have been taken and arrows highlight
apoptotic cells. Overall, no differences are seen between Cx3cr1-/- and wild type mice. Scale bar corresponds to 2 mm (A, F), 400 μm (B, C, D, G, H, I)
or 100 μm (E, J).
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We have shown that Cx3cr1 deficiency results in an ac-
celeration in the onset of the clinical signs of prion dis-
ease, as illustrated by shorter incubation times, with
three different prion strains. These data suggest that in
wild type animals intact Cx3cl1/Cx3cr1 signalling is par-
tially protective and may act to somewhat restrain the
microglial response. The difference in incubation time
observed in knockout mice is quantitatively modest but
highly statistically significant with a reduction of 4%
for Chandler/RML and 7% for both ME7 and MRC2
prion strains and no overall differences observed in
microglial activation either by neuropathology or cyto-
kine/chemokine expression in terminally sick mice.
These data suggest that Cx3cl1/Cx3cr1 signalling plays
only a minor role in modulating microglial activation
in prion disease.
Although microglial activation was unaltered in our
study it is worth noting that for both neuropathological
examination and cytokine/chemokine production, we
looked only at brains from terminally sick animals. It is
possible that microglia are activated earlier in the ab-
sence of Cx3cr1 but by end stage disease microglia are
activated and distributed as seen in wild type mice. Ifmicroglia are activated earlier in Cx3cr1-/- mice the earl-
ier exposure to neurotoxic factors may contribute to the
earlier onset of clinical disease. We observed a 2-fold in-
crease in Il-12b expression in Cx3cr1-/- relative to
Cx3cr1+/+ mice (P = 0.01) but only with the ME7 prion
strain which suggests a prion strain specific effect. Given
that this was not observed with other proinflammatory
cytokines or with the other prion strains it is difficult to
assess the relevance of this finding.
The role of Cx3cl1/Cx3cr1 signalling in neurodegener-
ation is variable, highly dependent on the model used
and the phenotype measured and probably reflects the
nature of the neuroinflammatory response triggered by
each disease process. Our data suggest that for prion
disease the neuronal-microglia cross talk provided by
this interaction is partially protective but is not sufficient
to override other pathways of microglial activation or
neuronal loss. The protective role of Cx3cl1/Cx3cr1 is
also seen in models of AD (APPPS1 and R1.40), ALS
(TgSOD1G93A), tauopathy and PD [8-11]. This suggests
that different neurodegenerative diseases share common
pathways that ultimately contribute to neuronal death
and that the relative importance of each pathway is gov-
erned by the nature of the original insult.
Figure 4 MRC2 neuropathology. Histological features of MRC2 prion transmission to Cx3cr1-/- (A-E) and wild type control (F-J) mice. Panels A
and F show the global distribution of disease-associated PrP using anti-PrP monoclonal antibody ICSM35. Panels B, C, G and H show staining of
microglia with Iba-1 in the hippocampus (B, G) and the thalamus (C, H). Panels D, E, I and J are stained with haematoxylin and eosin (H&E) to
visualise spongiosis and neuronal loss in the hippocampus. Boxes show where the higher power images have been taken and arrows highlight
apoptotic cells. Overall, no differences are seen between Cx3cr1-/- and wild type mice. Scale bar corresponds to 2mm (A, F), 400 μm (B, C, D, G, H, I)
or 100 μm (E, J).
Figure 5 Chemokine/cytokine mRNA expression. Quantification of chemokine/cytokine mRNA expression from half mouse brain by real-time
RT-PCR. N = 5 for all groups (except uninfected control, wild type mice where n = 4) and samples were run in triplicate. All samples were duplexed
for the chemokine/cytokine (Fam-label) and an endogenous control GAPDH or β-actin (Vic-label). Expression level is shown as the fold difference
between the wild type uninfected control and all other groups (y-axis). Error bars represent the standard deviation. (A) Cxcl10, (B) Il-12b, (C) Il-1b,
(D) Arg-1. WT = wild type Cx3cr1+/+, KO = Cx3cr1-/-. *P = 0.01 (T-test). For A (P < 0.01), B (P < 0.05) and C (P < 0.01) expression levels for all infected
samples are significantly increased relative to the uninfected controls. No statistically significant differences were seen for D.
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We have demonstrated that loss of Cx3cr1 results in an
acceleration of onset of prion disease with three distinct
prion strains (Chandler/RML, ME7 and MRC2) suggest-
ing that intact Cx3cl1/Cx3cr1 signalling is partially pro-
tective in prion disease. This occurs in the context of
unchanged microglial activation, as assessed by cellular
distribution and cytokine profiles. The role of Cx3cl1/
Cx3cr1 signalling in different models of neurodegenera-
tion is highly variable suggesting that its influence is
dependent on the precise cytokine environment created
by each disease process.
Additional files
Additional file 1: Methods-western blotting and additional figure
legends.
Additional file 2: Figure S1. Western blots of PrPSc from infected
mouse brains.
Additional file 3: Figure S2. Cx3cl1 mRNA expression.
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